– EMERALD Study will investigate the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with end-stage liver disease – Recruitment already underway in the U.K., following recent MHRA approval EDINBURGH, Scotland […]
Tag: Resolution Therapeutics
Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease
– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic […]
Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth […]
